HRP20201219T1 - Anti-vla-4 antitijela - Google Patents
Anti-vla-4 antitijela Download PDFInfo
- Publication number
- HRP20201219T1 HRP20201219T1 HRP20201219TT HRP20201219T HRP20201219T1 HR P20201219 T1 HRP20201219 T1 HR P20201219T1 HR P20201219T T HRP20201219T T HR P20201219TT HR P20201219 T HRP20201219 T HR P20201219T HR P20201219 T1 HRP20201219 T1 HR P20201219T1
- Authority
- HR
- Croatia
- Prior art keywords
- sequence
- framework
- pharmaceutical preparation
- patient
- substituted
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 101000989058 Homo sapiens Immunoglobulin heavy variable 1-69-2 Proteins 0.000 claims 1
- 101000604674 Homo sapiens Immunoglobulin kappa variable 4-1 Proteins 0.000 claims 1
- 102100029422 Immunoglobulin heavy variable 1-69-2 Human genes 0.000 claims 1
- 102100038198 Immunoglobulin kappa variable 4-1 Human genes 0.000 claims 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
Claims (6)
1. Farmaceutski pripravak koji sadrži rekombinantnu molekulu antitijela, ili njezin fragment koji veže α4, koji sadrži varijabilni teški lanac i varijabilni laki lanac, naznačen time što:
(a) varijabilni teški lanac sadrži okvirnu sekvencu varijabilnog teškog lanca od IGHV1-f i CDRs iz VH lanca mišjeg antitijela HP1/2, pri čemu CDR1 sadrži sekvencu GFNIKDTYM, CDR2 sadrži sekvencu RIDPASGDTKYDPKFQV i CDR3 sadrži sekvencu GMWVSTGYALDF, i aminokiselinski ostaci u okvirnim položajima 24 i 94 varijabilnog teškog lanca prema shemi numeriranja Kabat su supstituirani, pri čemu je supstituirani ostatak u okvirnom položaju 24 alanin (A) i supstituirani ostatak u okvirnom položaju 94 je aspartanska kiselina (D);
(b) varijabilni laki lanac sadrži okvirnu sekvencu varijabilnog lakog lanca iz IGKV4-1 i CDRs iz VL lanca mišjeg antitijela HP1/2, pri čemu CDR1 sadrži sekvencu KASQSVTNDVA, CDR2 sadrži sekvencu YASNRYT i CDR3 sadrži sekvencu QQDYSSPYT i aminokiselinski ostaci u okvirnim položajima 1,67 i 87 varijabilnog lakog lanca prema shemi numeriranja Kabat su supstituirani, pri čemu supstituirani ostatak u okvirnom položaju 1 je serin (S), supstituirani ostatak u okvirnom položaju 67 je tirozin (Y) i supstituirani ostatak u okvirnom položaju 87 je fenilalanin (F);
i pri čemu se rekombinantna molekula antitijela ili njezin fragment koji veže α4 veže VLA-4.
2. Farmaceutski pripravak prema zahtjevu 1, za uporabu kao lijek u liječenju pacijenta.
3. Farmaceutski pripravak za uporabu prema zahtjevu 2, naznačen time što pacijent ima rak.
4. Farmaceutski pripravak za uporabu prema zahtjevu 3, naznačen time što pacijent ima solidan tumor, hematološku malignost, multipli mijelom ili akutnu mijelogenu leukemiju (AML).
5. Farmaceutski pripravak za uporabu prema zahtjevu 2, naznačen time što pacijent ima upalni poremećaj, multiplu sklerozu, astmu, reumatoidni artritis, dijabetes, optički neuritis, Crohnovu bolest, akutni poremećaj, ozljedu leđne moždine ili traumatološku ozljedu mozga.
6. Farmaceutski pripravak za uporabu prema zahtjevu 2, naznačen time što liječenje nadalje sadrži davanje pacijentu drugog terapeutskog sredstva, izborno odabranog od trombolitičkog sredstva, kemoterapeutskog sredstva, neuroprotektivnog sredstva, protuupalnog sredstva, steroida, citokina, ili faktora rasta.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32494410P | 2010-04-16 | 2010-04-16 | |
EP17163411.6A EP3202789B1 (en) | 2010-04-16 | 2011-04-15 | Anti-vla-4 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201219T1 true HRP20201219T1 (hr) | 2021-02-05 |
Family
ID=44628095
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171045TT HRP20171045T1 (hr) | 2010-04-16 | 2017-07-10 | Protutijela anti-vla-4 |
HRP20201219TT HRP20201219T1 (hr) | 2010-04-16 | 2020-08-03 | Anti-vla-4 antitijela |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171045TT HRP20171045T1 (hr) | 2010-04-16 | 2017-07-10 | Protutijela anti-vla-4 |
Country Status (24)
Country | Link |
---|---|
US (5) | US20140161794A1 (hr) |
EP (4) | EP4032912A1 (hr) |
JP (5) | JP6085554B2 (hr) |
KR (1) | KR20130066584A (hr) |
CN (1) | CN103038257A (hr) |
AU (1) | AU2011239512B2 (hr) |
BR (1) | BR112012026403B1 (hr) |
CA (1) | CA2794863C (hr) |
CY (2) | CY1119154T1 (hr) |
DK (3) | DK3202789T3 (hr) |
EA (1) | EA201291065A1 (hr) |
ES (3) | ES2912934T3 (hr) |
HR (2) | HRP20171045T1 (hr) |
HU (2) | HUE035098T2 (hr) |
LT (2) | LT2558499T (hr) |
ME (2) | ME03813B (hr) |
MX (1) | MX340683B (hr) |
NZ (1) | NZ602676A (hr) |
PL (3) | PL3202789T3 (hr) |
PT (2) | PT3202789T (hr) |
RS (2) | RS56082B1 (hr) |
SG (3) | SG10202112020VA (hr) |
SI (2) | SI2558499T1 (hr) |
WO (1) | WO2011130603A2 (hr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3202789T3 (pl) | 2010-04-16 | 2020-09-21 | Biogen Ma Inc. | Przeciwciała anty-vla-4 |
US20160152709A1 (en) * | 2013-07-05 | 2016-06-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
AU2016332725A1 (en) * | 2015-09-29 | 2018-03-22 | Celgene Corporation | PD-1 binding proteins and methods of use thereof |
EP3515943A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS |
US10751414B2 (en) | 2016-09-19 | 2020-08-25 | Celgene Corporation | Methods of treating psoriasis using PD-1 binding antibodies |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
JP2019136398A (ja) * | 2018-02-14 | 2019-08-22 | 株式会社三洋物産 | 遊技機 |
JP2019136399A (ja) * | 2018-02-14 | 2019-08-22 | 株式会社三洋物産 | 遊技機 |
US20210238289A1 (en) * | 2018-06-04 | 2021-08-05 | Biogen Ma Inc. | Anti-vla-4 antibodies having reduced effector function |
WO2021234560A1 (en) | 2020-05-19 | 2021-11-25 | Janssen Biotech, Inc. | Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor |
BR102020016890A2 (pt) | 2020-08-19 | 2022-05-03 | Fundação Oswaldo Cruz | Proteina, polinucleotídeo, vetor, célula hospedeira, composição, método para tratar uma doença, método in vitro para prognosticar esclerose múltipla, e, uso de uma proteína ou composição |
JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス,インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
AU2022278013A1 (en) | 2021-05-18 | 2024-01-18 | Janssen Biotech, Inc. | Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
JPS6081397A (ja) | 1983-10-06 | 1985-05-09 | 荒川化学工業株式会社 | 中性抄紙方法 |
US4494880A (en) | 1984-03-14 | 1985-01-22 | Su Wen Kuang | Foldable clock dial |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
HU196394B (en) | 1986-06-27 | 1988-11-28 | Richter Gedeon Vegyeszet | Process for preparing 2-halogenated ergoline derivatives |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
SE461013B (sv) | 1988-02-11 | 1989-12-18 | Christian Wesslau | Farmaceutisk komposition verksam mot lungobstruktioner bestaaende av en betaadrenerg antagonist och ett tyroideahormon |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5217870A (en) | 1989-04-28 | 1993-06-08 | Biogen, Inc. | Monoclonal antibodies against CDX |
US6307025B1 (en) | 1989-04-28 | 2001-10-23 | Biogen, Inc. | VCAM fusion proteins and DNA coding therefor |
US5272263A (en) | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
US5260210A (en) | 1989-09-27 | 1993-11-09 | Rubin Lee L | Blood-brain barrier model |
US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US5871734A (en) | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
DE69309044T3 (de) | 1992-01-13 | 2004-12-23 | Biogen, Inc., Cambridge | Behandlung von asthma |
US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
ATE151642T1 (de) | 1992-02-12 | 1997-05-15 | Biogen Inc | Behandlung für entzündungserkrankung des darmes |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
DE69309487T2 (de) | 1992-11-13 | 1997-10-23 | Univ Washington | Peripheralisierung hämatopoietischer stammzellen |
DK0678122T3 (da) | 1993-01-12 | 2000-03-06 | Biogen Inc | Rekombinante anti-VLA4 antistofmolekyler |
CA2155540A1 (en) | 1993-02-08 | 1994-08-18 | Frank Collins | Methods for treating amyotrophic lateral sclerosis with cntf |
ES2114183T5 (es) | 1993-02-09 | 2006-06-16 | Biogen Idec Ma, Inc. | Anticuerpo para el tratamiento de la diabetes dependiente de la insulina. |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6432404B1 (en) | 1993-12-23 | 2002-08-13 | Icos Corporation | Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies |
DK1759709T3 (da) | 1994-01-25 | 2013-06-10 | Elan Pharm Inc | Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4 |
US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US5672622A (en) | 1994-04-21 | 1997-09-30 | Berlex Laboratories, Inc. | Treatment of multiple sclerosis |
SE504751C2 (sv) | 1994-06-30 | 1997-04-21 | Lars Fredriksson | Kopplingslänk |
US5498156A (en) | 1994-09-02 | 1996-03-12 | Ipsco Enterprises Inc. | Dual-purpose guide and drum cleaner for Steckel mill coiler furnace |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
BRPI9715219B8 (pt) | 1996-02-09 | 2015-07-07 | Abbvie Biotechnology Ltd | Vetor recombinante de expressão, e célula hospedeira procariótica. |
JP2000516596A (ja) | 1996-07-25 | 2000-12-12 | バイオジェン,インコーポレイテッド | 細胞接着インヒビター |
US7361331B2 (en) | 1996-10-18 | 2008-04-22 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Plant bioreactors |
ATE387495T1 (de) | 1996-12-03 | 2008-03-15 | Amgen Fremont Inc | Vollkommen humane antikörper die egfr binden |
US6890526B2 (en) | 1997-05-06 | 2005-05-10 | Vanderbilt University | Methods and reagents for the treatment of multiple sclerosis |
EP1001975A1 (en) | 1997-07-31 | 2000-05-24 | Elan Pharmaceuticals, Inc. | Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4 |
US6153653A (en) | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
AU2203199A (en) | 1997-12-30 | 1999-07-19 | Bioabsorbable Concepts, Inc. | Tetracycline and/or tetracycline derivative(s) for treating, suppressing and preventing of cerebrovascular diseases of nervous system |
DK1082302T3 (da) | 1998-05-28 | 2004-04-26 | Biogen Inc | En VLA-4-inhibitor: oMePUPA-V |
US7232830B2 (en) | 1998-06-26 | 2007-06-19 | Elaine A Delack | Method for treatment of neurodegenerative diseases and effects of aging |
SI1113810T1 (sl) * | 1998-09-14 | 2009-04-30 | Univ Texas | Postopki za zdravljenje multiplega mieloma in kostne resorpcije, inducirane z mielomom, z uporabo antagonistov integrin/receptorske vezave |
US6355623B2 (en) | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
JP2002538167A (ja) | 1999-03-03 | 2002-11-12 | バイオジェン インコーポレイテッド | 脂質の代謝および貯蔵を調節する方法 |
AU2446801A (en) | 1999-12-23 | 2001-07-03 | Ancile Pharmaceuticals, Inc. | Treatment for inflammatory bowel disease (ibd) and related conditions |
AU2001233034A1 (en) | 2000-01-27 | 2001-08-07 | American Cyanamid Company | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
DE60142508D1 (de) | 2000-03-31 | 2010-08-19 | Scripps Research Inst | Menschliche aminoacyl-trna synthetase polypeptide zur regulation der angiogenese |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
US6537243B1 (en) | 2000-10-12 | 2003-03-25 | Abbott Laboratories | Device and method for obtaining interstitial fluid from a patient for diagnostic tests |
US6894033B2 (en) | 2001-06-11 | 2005-05-17 | Transition Therapeutics Inc. | Combination therapies using vitamin B12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases |
AU2002365279B2 (en) | 2001-12-17 | 2009-08-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
US20040203031A1 (en) | 2002-04-03 | 2004-10-14 | University Of Pennsylvania | Methods for determining drug responsiveness |
EP1480521B1 (en) | 2002-02-15 | 2015-02-25 | Cornell Research Foundation, Inc. | Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells |
AR038605A1 (es) | 2002-02-25 | 2005-01-19 | Elan Pharm Inc | Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento |
US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
EP3064215A1 (en) | 2002-10-16 | 2016-09-07 | Samuel F. Hunter | Method for treatment of demyelinating central nervous system disease |
ATE455853T1 (de) | 2002-11-22 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Antikörper gegen geschädigtes gewebe |
EP3527228A1 (en) | 2003-01-24 | 2019-08-21 | Biogen MA Inc. | Composition for a treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
DK2236154T3 (en) | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
US20050074443A1 (en) | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
AU2004290070A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
WO2005113003A2 (en) | 2004-04-16 | 2005-12-01 | Genentech, Inc. | Method for augmenting b cell depletion |
CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
RS57636B1 (sr) | 2004-09-03 | 2018-11-30 | Genentech Inc | Humanizovani anti-beta7 antagonisti i njihova upotreba |
CN103169965A (zh) * | 2004-11-19 | 2013-06-26 | 比奥根艾迪克Ma公司 | 治疗多发性硬化 |
JP2008522971A (ja) | 2004-12-03 | 2008-07-03 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 多発性硬化症の発症の遅延または予防 |
AU2006220709B2 (en) * | 2005-03-04 | 2012-09-06 | Biogen Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
AU2006254772B2 (en) | 2005-06-09 | 2011-06-02 | Ucb Pharma S.A. | 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament |
CA2652434A1 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized proteins that target ep-cam |
CN105381459A (zh) | 2006-05-25 | 2016-03-09 | 比奥根Ma公司 | 治疗中风的方法 |
WO2008021954A2 (en) | 2006-08-09 | 2008-02-21 | Biogen Idec Ma Inc. | Method for distribution of a drug |
US8771689B2 (en) | 2006-12-11 | 2014-07-08 | The Board Of Trustees Of The Leland Stanford Junior University | Alpha B-crystallin as a therapy for ischemia or inflammation |
US8931218B2 (en) | 2007-04-19 | 2015-01-13 | Oldcastle Building Products, Inc. | Modular brick or block outdoor structures |
US20090252729A1 (en) | 2007-05-14 | 2009-10-08 | Farrington Graham K | Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto |
TWI614028B (zh) | 2007-06-14 | 2018-02-11 | 百健Ma公司 | 抗體調配物 |
US20090004189A1 (en) | 2007-06-18 | 2009-01-01 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
DE102007049542A1 (de) | 2007-10-16 | 2009-04-23 | Neue Magnetodyn Gmbh | Implantierbare Vorrichtung, System zum Erzeugen lokalisierter elektromagnetischer Felder im Bereich eines Implantats und Spulenanordnung |
EP2050462A1 (en) | 2007-10-18 | 2009-04-22 | PAION Deutschland GmbH | Improved treatment of stroke patients |
PL3202789T3 (pl) | 2010-04-16 | 2020-09-21 | Biogen Ma Inc. | Przeciwciała anty-vla-4 |
AU2012325013A1 (en) | 2011-10-17 | 2014-03-27 | Westfaelische Wilhelms-Universitaet Muenster | Methods of risk assessment of PML and related apparatus |
-
2011
- 2011-04-15 PL PL17163411T patent/PL3202789T3/pl unknown
- 2011-04-15 RS RS20170701A patent/RS56082B1/sr unknown
- 2011-04-15 KR KR1020127027585A patent/KR20130066584A/ko not_active Application Discontinuation
- 2011-04-15 RS RS20200950A patent/RS60897B1/sr unknown
- 2011-04-15 EP EP21218415.4A patent/EP4032912A1/en active Pending
- 2011-04-15 SG SG10202112020VA patent/SG10202112020VA/en unknown
- 2011-04-15 CN CN2011800296749A patent/CN103038257A/zh active Pending
- 2011-04-15 WO PCT/US2011/032641 patent/WO2011130603A2/en active Application Filing
- 2011-04-15 LT LTEP11730120.0T patent/LT2558499T/lt unknown
- 2011-04-15 JP JP2013505169A patent/JP6085554B2/ja active Active
- 2011-04-15 PL PL18205524T patent/PL3466977T3/pl unknown
- 2011-04-15 PT PT171634116T patent/PT3202789T/pt unknown
- 2011-04-15 BR BR112012026403-6A patent/BR112012026403B1/pt active IP Right Grant
- 2011-04-15 SI SI201131238T patent/SI2558499T1/sl unknown
- 2011-04-15 ME MEP-2020-168A patent/ME03813B/me unknown
- 2011-04-15 CA CA2794863A patent/CA2794863C/en active Active
- 2011-04-15 ES ES18205524T patent/ES2912934T3/es active Active
- 2011-04-15 HU HUE11730120A patent/HUE035098T2/en unknown
- 2011-04-15 DK DK17163411.6T patent/DK3202789T3/da active
- 2011-04-15 DK DK18205524.4T patent/DK3466977T3/da active
- 2011-04-15 AU AU2011239512A patent/AU2011239512B2/en active Active
- 2011-04-15 ES ES11730120.0T patent/ES2633105T3/es active Active
- 2011-04-15 EP EP17163411.6A patent/EP3202789B1/en active Active
- 2011-04-15 EA EA201291065A patent/EA201291065A1/ru unknown
- 2011-04-15 PL PL11730120T patent/PL2558499T3/pl unknown
- 2011-04-15 MX MX2012012010A patent/MX340683B/es active IP Right Grant
- 2011-04-15 NZ NZ602676A patent/NZ602676A/en unknown
- 2011-04-15 PT PT117301200T patent/PT2558499T/pt unknown
- 2011-04-15 ME MEP-2017-148A patent/ME02793B/me unknown
- 2011-04-15 ES ES17163411T patent/ES2805873T3/es active Active
- 2011-04-15 LT LTEP17163411.6T patent/LT3202789T/lt unknown
- 2011-04-15 SG SG2012071999A patent/SG184318A1/en unknown
- 2011-04-15 EP EP11730120.0A patent/EP2558499B1/en active Active
- 2011-04-15 US US13/641,199 patent/US20140161794A1/en not_active Abandoned
- 2011-04-15 DK DK11730120.0T patent/DK2558499T3/en active
- 2011-04-15 SI SI201131902T patent/SI3202789T1/sl unknown
- 2011-04-15 EP EP18205524.4A patent/EP3466977B1/en active Active
- 2011-04-15 HU HUE17163411A patent/HUE050858T2/hu unknown
- 2011-04-15 SG SG10201502967RA patent/SG10201502967RA/en unknown
-
2017
- 2017-01-30 JP JP2017014410A patent/JP6525440B2/ja active Active
- 2017-07-10 CY CY20171100728T patent/CY1119154T1/el unknown
- 2017-07-10 HR HRP20171045TT patent/HRP20171045T1/hr unknown
- 2017-12-12 US US15/838,884 patent/US10335485B2/en active Active
-
2018
- 2018-05-15 JP JP2018093927A patent/JP2018123165A/ja not_active Withdrawn
-
2019
- 2019-06-14 US US16/441,974 patent/US11083791B2/en active Active
- 2019-10-09 JP JP2019185798A patent/JP2020019811A/ja active Pending
-
2020
- 2020-06-02 CY CY20201100516T patent/CY1122978T1/el unknown
- 2020-08-03 HR HRP20201219TT patent/HRP20201219T1/hr unknown
-
2021
- 2021-07-02 US US17/366,903 patent/US11571477B2/en active Active
-
2022
- 2022-07-22 JP JP2022117076A patent/JP2022141875A/ja active Pending
-
2023
- 2023-02-06 US US18/165,146 patent/US20240100155A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201219T1 (hr) | Anti-vla-4 antitijela | |
HRP20201595T1 (hr) | Anti-pd-l1 protutijela i njihova uporaba | |
RU2495050C2 (ru) | Связующий элемент для рецептора gm-csf | |
HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
JP2019529373A5 (ja) | 抗Tim−3抗体 | |
HRP20200887T1 (hr) | Smjese za inhibiciju masp-2 ovisne aktivacije komplementa | |
HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
RU2019141289A (ru) | АНТИ-SIRPα АНТИТЕЛА | |
RU2020124191A (ru) | Анти-tigit антиген-связывающие белки и способы их применения | |
RU2017105915A (ru) | Антитела против pd-1 | |
HRP20211280T1 (hr) | Anti-5t4 antitijela i konjugati antitijelo-lijek | |
RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы | |
RU2015102069A (ru) | Антитела к биотину и способы их применения | |
HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
SI2906296T1 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
JP2015534579A5 (hr) | ||
JP2011514150A5 (hr) | ||
RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
JP2014511179A5 (hr) | ||
JP2015506912A5 (hr) | ||
RU2009149462A (ru) | АНТИТЕЛА ПРОТИВ NRR Notch1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
JP2016536020A5 (hr) | ||
RU2014120757A (ru) | Связывающие молекулы, специфичные по отношению к her3, и их применения |